VetPlus Kaminox 30 Sachets for Dogs & Cats | Potassium Gluconate, B-Vitamins, Taurine & L-Carnitine | Hypokalaemia, CKD Potassium Support & Feline Polymyopathy Management

FOR ANIMAL USE ONLY — Administer as directed by a veterinarian. VetPlus Kaminox is a veterinary nutraceutical potassium and B-vitamin supplement — not a veterinary medicine. Kaminox is not a substitute for veterinary diagnosis and management of hypokalaemia, chronic kidney disease (CKD), or feline hypokalaemic polymyopathy. Hypokalaemia in dogs and cats is a medical condition requiring serum potassium confirmation by a veterinarian before initiating potassium supplementation — do not supplement potassium without veterinary diagnosis. In animals with oliguria, anuria, urethral obstruction, hypoadrenocorticism (Addison’s disease), or concurrent ACE-inhibitor therapy (enalapril, benazepril, ramipril — which reduce renal potassium excretion via aldosterone suppression), potassium supplementation requires veterinary supervision and serum monitoring to avoid hyperkalaemia (a life-threatening cardiac arrhythmia risk: K+ >7.0 mmol/L → tall peaked T waves → QRS widening → sine wave → ventricular fibrillation). Keep out of reach of children. Store in a cool, dry place; keep sachets sealed until use.

VetPlus Kaminox 30 Sachets for Dogs & Cats | Potassium Gluconate, B-Vitamins, Taurine & L-Carnitine | Hypokalaemia, CKD Potassium Support & Feline Polymyopathy Management

VetPlus Kaminox is a veterinary nutraceutical potassium and B-vitamin supplement manufactured by VetPlus Ltd (UK), formulated to maintain or restore serum potassium concentrations and support B-vitamin, taurine, and L-carnitine status in dogs and cats with potassium depletion, particularly those with chronic kidney disease (CKD), polyuria, and dietary restriction. Kaminox delivers potassium as potassium gluconate (the organic potassium salt preferred over potassium chloride [KCl] for its superior palatability and GI tolerability — KCl is intensely bitter and causes GI mucosal irritation, significantly limiting compliance in cats; potassium gluconate is readily absorbed and does not contribute to acid-base disturbance unlike KCl which provides chloride load), together with the B-vitamins lost in polyuric urine (B1 thiamine, B2 riboflavin, B6 pyridoxine, B12 cyanocobalamin), vitamin E, taurine (the conditionally essential amino acid in cats), and L-carnitine (the mitochondrial fatty acid shuttle). 30-sachet pack = 30-day supply at 1 sachet daily. The liquid-to-mix or palatable powder sachet format is specifically designed for cats — the species with the highest clinical burden of hypokalaemia from CKD-associated potassium wasting.

Feline CKD and Potassium Physiology: Why Cats are Disproportionately Affected

• The feline CKD epidemic and potassium wasting — why Kaminox is primarily a feline product: feline CKD (chronic kidney disease — IRIS [International Renal Interest Society] staging: Stage 1 creatinine <140 μmol/L; Stage 2 140–249 μmol/L; Stage 3 250–439 μmol/L; Stage 4 >440 μmol/L; with symmetric dimethylarginine [SDMA] as the earlier biomarker [IRIS SDMA Stage 1 >14 μg/dL]) affects approximately 30–40% of cats over 10 years of age and over 80% of cats over 15 years — the most prevalent chronic disease of aged cats globally; the primary mechanism of potassium depletion in feline CKD is multifactorial: (a) obligate renal potassium wasting from polyuria: in CKD, the remaining nephron population cannot concentrate urine (the concentrating mechanism — the countercurrent multiplier system of the loop of Henle — requires a critical nephron mass to generate the medullary interstitial osmotic gradient; in CKD, progressive nephron loss reduces the corticomedullary osmotic gradient → obligate isosthenuria at approximately 1.007–1.015 specific gravity); polyuria (urine volume compensatorily increased to maintain solute excretion despite fixed isosthenuric urine concentration) → obligate potassium urinary loss (potassium is freely filtered at the glomerulus; the principal cell of the cortical collecting duct [CCD] — the ROMK [Kir1.1/KCNJ1] potassium channel and the BK [maxi-K/KCNMA1/Slo1] potassium channel — are the primary urinary potassium secretory pathways; in polyuria, increased tubular flow rate activates BK channels via flow-sensitive gating → enhanced K+ secretion → urinary K+ wasting proportional to urine volume); (b) metabolic acidosis-driven intracellular potassium shift: CKD causes metabolic acidosis (reduced tubular NH3/NH4+ excretion capacity from loss of proximal tubular ammonia synthesis, and reduced distal H+ secretion from Type IV renal tubular acidosis [aldosterone resistance or reduced aldosterone response in the CKD collecting duct] → H+ accumulation → plasma [HCO3−] falls); metabolic acidosis → intracellular K+ shifts: (i) H+/K+ exchange via the plasma membrane H+/K+-ATPase → K+ moves from intracellular to extracellular in exchange for H+ entry — this is paradoxical in CKD: while acidosis transiently moves K+ extracellularly, the simultaneous renal and GI potassium losses from polyuria, anorexia, and vomiting ultimately result in net total body potassium depletion despite the acidosis-driven cellular shift; (ii) metabolic acidosis also directly suppresses renal tubular K+ reabsorption in the proximal tubule (H+/K+-ATPase competition); (c) reduced dietary intake: anorexia and hyporexia are ubiquitous in CKD cats → reduced K+ ingestion; renal diets deliberately restrict protein → reduced dietary potassium; (d) vomiting and GI losses: CKD-associated uraemic gastroenteritis causes vomiting → loss of gastric HCl → metabolic alkalosis (at high BUN [blood urea nitrogen]; the ‘uraemic vomiting’ paradox − gastric secretory activation by uraemic toxins → HCl loss → hypokalaemic metabolic alkalosis) AND direct GI K+ losses in vomit and diarrhoea
• Feline hypokalaemic polymyopathy — the pathognomonic clinical syndrome of potassium depletion in cats: serum K+ reference range cats: 3.5–4.9 mmol/L (equivalent to mEq/L; SI units); mild hypokalaemia: 3.0–3.4 mmol/L; moderate: 2.5–3.0 mmol/L; severe: <2.5 mmol/L; the pathognomonic and most diagnostically striking clinical sign of feline hypokalaemia is cervical ventroflexion: the cat’s head drops and the neck bends downward (ventral cervical flexion) because the epaxial cervical extensor muscles (biventer cervicis, complexus, splenius, semispinalis capitis) are preferentially weakened by hypokalaemia; mechanism of hypokalaemic myopathy: hypokalaemia → hyperpolarisation of skeletal muscle cell membranes (the resting membrane potential [RMP] of skeletal muscle is determined by the Nernst equation for K+: E_K = (RT/zF) × ln([K+]e/[K+]i); [K+]e decreases in hypokalaemia → the Nernst K+ equilibrium potential becomes more negative → the RMP hyperpolarises further from threshold → muscle cells require a larger depolarising stimulus to reach the action potential threshold → reduced neuromuscular excitability → muscle weakness; the mechanism is the opposite of hyperkalaemia [which depolarises and inactivates voltage-gated Na+ channels → also causing weakness but by Na+ channel inactivation rather than hyperpolarisation]); generalised hypokalaemic polymyopathy: symmetrical proximal limb weakness, reluctance to walk, muscle pain on palpation, and the pathognomonic cervical ventroflexion; in severe cases, rhabdomyolysis (hypokalaemia → impaired Na+/K+-ATPase energy supply → reduced ability of muscle cells to maintain Na+/K+ gradients → Na+ and Ca2+ intracellular accumulation → mitochondrial Ca2+ overload → caspase and calpain activation → myofibril degradation → myoglobinuria [the urine turns red/brown] → myoglobin-mediated acute tubular necrosis [ATN] → acute-on-chronic renal failure); serum CK (creatine kinase) is markedly elevated in hypokalaemic myopathy (>5000 U/L and often >10,000 U/L in severe cases — CK is the standard marker of skeletal muscle damage: CK-MM isoform from skeletal muscle [90% of total CK] vs CK-MB from cardiac muscle [normally <5% in healthy cats] vs CK-BB from brain); potassium gluconate supplementation with Kaminox → restoration of [K+]e → correction of RMP hyperpolarisation → restoration of neuromuscular excitability → resolution of cervical ventroflexion and polymyopathy

Active Ingredients & Mechanisms

• Potassium gluconate — the bioavailable, palatable organic potassium salt: potassium gluconate (C6H11KO7 — the potassium salt of gluconic acid [the C1-oxidation product of glucose]; MW 234.25 g/mol; provides approximately 16.7% K+ by weight → each gram of potassium gluconate provides approximately 167 mg or 4.3 mEq K+); organic potassium salts (gluconate, citrate) are preferred over KCl in veterinary oral supplementation for: (a) palatability — KCl is intensely bitter (detected at threshold 0.0003 mol/L by feline T2R bitter taste receptors; potassium gluconate is near-tasteless at equivalent K+ doses); (b) GI tolerability — KCl causes dose-dependent gastric mucosal irritation and erosion (particularly in slow-release formulations; chronic-release KCl tablets cause small intestinal ulceration/stenosis in humans — not used in cats); potassium gluconate’s gluconate anion is readily absorbed and metabolised → minimal GI irritation; (c) acid-base neutrality/alkalinising tendency: gluconate (like citrate) is an organic anion that is metabolised to HCO3− in the liver (gluconate + NAD+ → glucuronate → via the uronic acid pathway and glucuronate reductase → ultimately to CO2 + H2O via TCA; net effect is consumption of H+ → mild alkalinising effect − potentially beneficial in CKD-associated metabolic acidosis; in contrast, KCl supplementation provides Cl− → worsens hyperchloraemic metabolic acidosis in CKD)
• B-vitamins (B1 thiamine, B2 riboflavin, B6 pyridoxine, B12 cyanocobalamin) — water-soluble vitamins lost in CKD polyuria: all B vitamins are water-soluble and are freely filtered at the glomerulus (not protein-bound in plasma); polyuria in CKD → obligate urinary B-vitamin losses proportional to urine volume; (a) thiamine (B1/TPP) — the most critically deficient B-vitamin in feline CKD: PDH [pyruvate dehydrogenase] and α-KGDH [α-ketoglutarate dehydrogenase] cofactor → thiamine deficiency in CKD cats → thiamine-responsive polioencephalomyelopathy (midbrain/brainstem neuronal necrosis — olivary nuclei, caudal colliculi → vestibular signs, seizures; cats are uniquely vulnerable due to their 50× higher cerebral glucose oxidation rate vs dogs); thiamine is the B vitamin with no hepatic storage → depletion occurs within 2 weeks of reduced intake; (b) riboflavin (B2/FAD/FMN) — mitochondrial ETC Complex I and II cofactor; fatty acid beta-oxidation [ACAD enzymes]; (c) pyridoxine (B6/PLP) — over 140 PLP-dependent enzyme cofactor; particularly relevant in CKD: oxalate synthesis regulation (alanine-glyoxylate aminotransferase [AGT − the primary glyoxylate detoxification enzyme, converting glyoxylate → glycine] is PLP-dependent − pyridoxine deficiency → glyoxylate accumulates → oxidised to oxalate → calcium oxalate crystal deposition in renal tubules → tubular obstruction and nephrotoxicity); B6 deficiency therefore directly worsens renal injury in CKD cats; (d) cyanocobalamin (B12) — methionine synthase and methylmalonyl-CoA mutase cofactor; hypocobalaminaemia is documented in CKD cats (reduced ileal cubilin/megalin IF-B12 receptor expression in uraemic states; concurrent GI disease exacerbates); cobalamin deficiency → methylmalonic acidaemia (MMA) → propionate accumulation → direct renal tubular toxicity and worsening of CKD acidosis
• Vitamin E (d-alpha-tocopherol) — antioxidant against CKD-associated oxidative stress: CKD generates sustained systemic oxidative stress via: uraemic toxin-driven NADPH oxidase activation in renal tubular cells, endothelial cells, and circulating monocytes → •O2− → H2O2 → •OH; reduced renal clearance of advanced glycation end products (AGEs) and advanced oxidation protein products (AOPPs) → RAGE/TLR4-mediated NF-κB activation → proinflammatory cytokine (IL-6, TNF-α, IL-1β) production; vitamin E (tocopheroxyl radical chain termination → LOO• + TH → LOOH + T• → recycled by ascorbate/GSH) scavenges PUFA lipid peroxyl radicals in renal tubular cell membranes; clinical evidence: Solomon et al. demonstrated reduced oxidative stress markers in CKD cats with antioxidant supplementation; vitamin E protects renal tubular cell plasma membrane PUFAs from lipid peroxidation-mediated cell death (LPO-mediated nephron loss accelerates CKD progression)
• Taurine — the conditionally essential amino acid in cats with specific renal and cardiac relevance in CKD: taurine (2-aminoethane-1-sulfonic acid; the sulfonic acid analogue of beta-alanine; MW 125.15 g/mol) is uniquely indispensable in cats: (a) bile acid conjugation: cats exclusively conjugate bile acids with taurine (via bile acid:CoA ligase [BACL] + bile acid:amino acid N-acyltransferase [BAAT] → tauro-conjugates including taurocholic acid, taurochenodeoxycholic acid) − unlike dogs which conjugate with both glycine and taurine (and glycine becomes predominant when taurine is limiting); taurine-conjugated bile acids are essential for normal fat emulsification and fat-soluble vitamin (A, D, E, K) absorption in the feline small intestine; taurine depletion in CKD cats (urinary taurine wasting via polyuria + reduced dietary protein intake) → impaired bile acid conjugation → fat malabsorption → fat-soluble vitamin deficiency → worsening of the overall nutritional status in CKD cats; (b) feline dilated cardiomyopathy (DCM) prevention: taurine deficiency causes DCM in cats (confirmed by Pion et al., Science 1987 — the landmark discovery of taurine deficiency as the cause of feline DCM, reversible with supplementation); taurine-deficient DCM is characterised by myocardial failure, cardiomegaly, and left atrial thrombus with aortic thromboembolism (ATE — the ‘saddle thrombus’ causing acute hindlimb paresis/paralysis, cold extremities, and cyanotic paw pads — a life-threatening emergency); in CKD cats, the concurrent risk of taurine depletion and DCM development from polyuria-driven taurine wasting makes taurine supplementation a critical component of Kaminox’s CKD management formulation; (c) osmoregulation: taurine is an organic osmolyte in the renal medullary cells (the inner medullary collecting duct [IMCD] cells and loop of Henle epithelial cells regulate cell volume under hyperosmotic stress via accumulation of compatible organic osmolytes: taurine, myo-inositol, betaine, sorbitol via the betaine/GABA transporter [BGT1/SLC6A12] and the taurine transporter [TauT/SLC6A6]); in CKD-associated medullary tonicity dysregulation, taurine’s role as a compatible osmolyte in medullary cells is compromised → medullary cell volume dysregulation → further loss of the countercurrent concentrating mechanism
• L-Carnitine — the mitochondrial fatty acid shuttle with specific relevance to hypokalaemic myopathy and CKD muscle wasting: L-carnitine (β-hydroxy-γ-trimethylaminobutyric acid; MW 161.20 g/mol; the R-stereoisomer is biologically active) is the obligate carrier molecule for long-chain fatty acyl groups (≥8 carbon chain length) across the inner mitochondrial membrane (IMM) for beta-oxidation: long-chain acyl-CoA (LCFA-CoA) + carnitine → CPT1 (carnitine palmitoyltransferase 1 − outer IMM; CPT1a liver isoform, CPT1b muscle isoform) → acylcarnitine → CACT (carnitine-acylcarnitine translocase − the IMM antiporter exchanging acylcarnitine for free carnitine) → acylcarnitine enters the mitochondrial matrix → CPT2 (carnitine palmitoyltransferase 2 − inner IMM matrix face) → acyl-CoA + carnitine (free carnitine returns to the cytosol via CACT); without carnitine, long-chain fatty acids cannot be beta-oxidised → cells switch to glucose as primary energy substrate (increasing demand on thiamine-dependent PDH − the convergent vulnerability with thiamine deficiency in CKD); in CKD cats: (a) urinary carnitine losses via polyuria (carnitine MW 161 − freely filtered at the glomerulus; reduced tubular reabsorption in CKD ‒ the OCTN2 [SLC22A5] sodium-carnitine cotransporter is expressed in the proximal renal tubule and provides most of the tubular carnitine reabsorption; CKD-associated proximal tubular dysfunction reduces OCTN2 activity → carnitine urinary wasting); (b) reduced dietary carnitine intake from protein restriction and anorexia (carnitine is primarily derived from red meat − the richest dietary source; renal diets restrict protein/meat → reduced dietary carnitine); (c) hypokalaemia − carnitine synergy: hypokalaemia-associated myopathy causes impaired myofibril function independent of carnitine depletion, but concurrent carnitine depletion in CKD cats means that even partial potassium restoration may not fully restore muscle function without addressing the parallel carnitine deficiency in muscle mitochondrial fatty acid energy supply; Kaminox’s combination of potassium gluconate + L-carnitine addresses both the RMP hyperpolarisation (potassium) and the mitochondrial energy substrate supply (carnitine) simultaneously in hypokalaemic CKD cats

Indications

• Feline hypokalaemia — the primary indication: serum K+ <3.5 mmol/L confirmed by a veterinarian, from any cause
• Feline CKD (IRIS Stage 1–4) — daily potassium, B-vitamin, taurine, and carnitine maintenance supplementation
• Feline hypokalaemic polymyopathy — cervical ventroflexion, generalised muscle weakness, and elevated serum CK under veterinary management
• Canine hypokalaemia — from CKD, Addison’s disease recovery (following fludrocortisone/DOCP stabilisation and with veterinary monitoring to confirm hypo- rather than hyperkalaemia), vomiting/diarrhoea-associated potassium losses
• Post-urethral obstruction in cats — post-obstructive diuresis causes massive polyuria → potassium wasting; Kaminox supports potassium repletion during the post-obstruction polyuric phase
• Concurrent B-vitamin supplementation in polyuric animals on renal diets

Directions for Use

• Administer as directed by a veterinarian; dosing is based on serum potassium concentration and body weight
• Mix the sachet contents into food or water daily
• 30-sachet pack = 30-day supply at 1 sachet daily; chronic CKD management typically requires ongoing supplementation with periodic serum K+ monitoring (every 4–8 weeks in stable CKD cats)
• Recheck serum K+ after 2–4 weeks of supplementation to confirm adequate response and adjust dose as directed by a veterinarian

Safety Information

• For animal use only — keep out of reach of children
• CRITICAL: Do not supplement potassium without a confirmed serum potassium measurement by a veterinarian; potassium supplementation in hyperkalaemic animals (Addison’s disease pre-treatment, urethral obstruction, oliguric renal failure) is life-threatening
• Monitor serum potassium during supplementation; excess potassium in anuric or oliguric animals → hyperkalaemia → cardiac arrhythmia
• Store in a cool, dry place; keep sachets sealed until use